1. Home
  2. BLIN vs BIVI Comparison

BLIN vs BIVI Comparison

Compare BLIN & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bridgeline Digital Inc.

BLIN

Bridgeline Digital Inc.

N/A

Current Price

$0.75

Market Cap

12.1M

Sector

Technology

ML Signal

N/A

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.19

Market Cap

12.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLIN
BIVI
Founded
2000
2013
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.1M
12.7M
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
BLIN
BIVI
Price
$0.75
$1.19
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $5.26
AVG Volume (30 Days)
52.3K
★ 224.1K
Earning Date
08-13-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 74.83
EPS
★ N/A
N/A
Revenue
★ $13,568,000.00
N/A
Revenue This Year
$20.26
N/A
Revenue Next Year
$21.08
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.69
$0.82
52 Week High
$1.42
$3.79

Technical Indicators

Market Signals
Indicator
BLIN
BIVI
Relative Strength Index (RSI) 30.35 31.69
Support Level $0.70 $1.10
Resistance Level $1.05 $1.32
Average True Range (ATR) 0.07 0.09
MACD -0.00 -0.03
Stochastic Oscillator 7.33 9.18

Price Performance

Historical Comparison
BLIN
BIVI

About BLIN Bridgeline Digital Inc.

Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

Share on Social Networks: